{"id":9244,"date":"2025-07-25T09:14:26","date_gmt":"2025-07-25T07:14:26","guid":{"rendered":"https:\/\/www.igmm.cnrs.fr\/une-avancee-scientifique-majeure-issue-du-laboratoire-cooperatif-abivax-et-de-lequipe-tazi-a-ligmm\/"},"modified":"2025-07-25T16:30:29","modified_gmt":"2025-07-25T14:30:29","slug":"une-avancee-scientifique-majeure-issue-du-laboratoire-cooperatif-abivax-et-de-lequipe-tazi-a-ligmm","status":"publish","type":"post","link":"https:\/\/www.igmm.cnrs.fr\/en\/une-avancee-scientifique-majeure-issue-du-laboratoire-cooperatif-abivax-et-de-lequipe-tazi-a-ligmm\/","title":{"rendered":"A Major Scientific Breakthrough from the Abivax Joint Laboratory and the Tazi Team at IGMM"},"content":{"rendered":"<div class=\"moz-cite-prefix\" style=\"text-align: justify;\">\n<figure id=\"attachment_9252\" aria-describedby=\"caption-attachment-9252\" style=\"width: 450px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-9252\" src=\"https:\/\/www.igmm.cnrs.fr\/wp-content\/uploads\/2025\/07\/ABIVAX-450x273.jpg\" alt=\"\u00a9 Fr\u00e9d\u00e9rique PLAS\/IGMM\/CNRS Images\" width=\"450\" height=\"273\" srcset=\"https:\/\/www.igmm.cnrs.fr\/wp-content\/uploads\/2025\/07\/ABIVAX-450x273.jpg 450w, https:\/\/www.igmm.cnrs.fr\/wp-content\/uploads\/2025\/07\/ABIVAX.jpg 700w\" sizes=\"auto, (max-width: 450px) 100vw, 450px\" \/><figcaption id=\"caption-attachment-9252\" class=\"wp-caption-text\">\u00a9 Fr\u00e9d\u00e9rique PLAS\/IGMM\/CNRS Images<\/figcaption><\/figure>\n<p>On July 23, 2025, the <a href=\"https:\/\/www.abivax.com\/\" target=\"_blank\" rel=\"noopener\">French biotech company Abivax<\/a> announced highly positive Phase 3 results from two clinical trials evaluating the efficacy of its drug obefazimod for the treatment of ulcerative colitis (UC).<\/p>\n<p><a href=\"https:\/\/ir.abivax.com\/static-files\/dd0f1ec1-7726-4213-8d5e-682daaeacfe3\" target=\"_blank\" rel=\"noopener\">This innovative therapy targets microRNA miR-124 <\/a>\u2014 a novel mechanism discovered through fundamental research by Professor Jamal Tazi\u2019s team at IGMM (CNRS \/ University of Montpellier), in collaboration with the Abivax joint laboratory in Montpellier.<\/p>\n<p>The announcement made headlines on the financial markets: Abivax\u2019s stock surged by over 520%, an event reported in <a href=\"https:\/\/www.lemonde.fr\/economie\/article\/2025\/07\/24\/la-biotech-tricolore-abivax-s-envole-de-520-en-bourse_6623398_3234.html\" target=\"_blank\" rel=\"noopener\">Le Monde<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>On July 23, 2025, the French biotech company Abivax announced highly positive Phase 3 results from two clinical trials evaluating the efficacy of its drug obefazimod for the treatment of ulcerative colitis (UC). This innovative therapy targets microRNA miR-124 \u2014 a novel mechanism discovered through fundamental research by Professor Jamal Tazi\u2019s team at IGMM (CNRS \/ University of Montpellier), in &hellip; <a href=\"https:\/\/www.igmm.cnrs.fr\/en\/une-avancee-scientifique-majeure-issue-du-laboratoire-cooperatif-abivax-et-de-lequipe-tazi-a-ligmm\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">A Major Scientific Breakthrough from the Abivax Joint Laboratory and the Tazi Team at IGMM<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":9252,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,16],"tags":[],"class_list":["post-9244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-news","category-science-en"],"_links":{"self":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/9244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/comments?post=9244"}],"version-history":[{"count":6,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/9244\/revisions"}],"predecessor-version":[{"id":9264,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/posts\/9244\/revisions\/9264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/media\/9252"}],"wp:attachment":[{"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/media?parent=9244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/categories?post=9244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.igmm.cnrs.fr\/en\/wp-json\/wp\/v2\/tags?post=9244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}